You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
明德生物(002932.SZ):2021年度淨利預增177.23%-219.88%
格隆匯 01-04 20:49

格隆匯1月4日丨明德生物(002932.SZ)發佈2021年年度業績預吿,2021年1月1日至2021年12月31日,公司預計歸屬於上市公司股東的淨利潤13億元-15億元,比上年同期增長177.23%-219.88%;歸屬於上市股東的扣除非經常性損益後的淨利潤13億元-15億元,比上年同期增長185.66%-229.61%;基本每股收益13.71元/股-15.83元/股。

疫情爆發以來公司新增了1,500多家分子診斷等級醫療機構客户,基於家疫情防控的要求,公司持續為上述客户提供新冠核酸檢測綜合解決方案,帶來公司新冠核酸檢測試劑銷售大幅增長。

報吿期內,公司研發的新型冠狀病毒抗原檢測試劑盒獲得了歐盟CE認證,並先後完成德國BfArM、英國MHRA、法國ANSM、意大利MDS、奧地利BASG、波蘭MZ、孟加拉國MOHFW、馬來西亞MDA、越南MOH等國家註冊/備案。受德爾塔和奧密克戎疫情影響,歐洲、東南亞等國家和地區新冠感染病例持續反覆並居高不下,導致對新冠抗原檢測試劑和核酸檢測試劑需求增加,公司海外新冠檢測試劑外貿訂單及相關收入大幅增長。

公司深耕三年的急危重症信息化解決方案持續迭代升級,在基層醫療和等級醫院中滲透率逐步提高,相關收入穩步增加。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account